Summit Therapeutics
SMMT
212 hedge funds and large institutions have $1.91B invested in Summit Therapeutics in 2025 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 79 increasing their positions, 69 reducing their positions, and 33 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
27% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 33
15% more capital invested
Capital invested by funds: $1.65B → $1.91B (+$255M)
14% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 69
4% more funds holding
Funds holding: 203 → 212 (+9)
0.83% more ownership
Funds ownership: 12.56% → 13.39% (+0.83%)
31% less call options, than puts
Call options by funds: $45.5M | Put options by funds: $65.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$26.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.7M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$25.6M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$18.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$23.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$15.1M |
| 3 |
Goldman Sachs
New York
|
-$6.76M |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$4.48M |
| 5 |
BCM
Boxer Capital Management
San Diego,
California
|
-$4.46M |
SMMT Hedge Fund Activity: Q1 2025 in Review
212 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2025, worth a combined $1.91B — up 15% from $1.65B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new SMMT positions and 33 closed out — a net gain of 9 holders — while 79 added to existing stakes and 69 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $26.4M. The largest seller was Millennium Management, cutting an estimated $23.3M.
- 212 institutional investors held Summit Therapeutics (SMMT) as of Q1 2025, up from 203 in Q4 2024.
- Funds reported $1.91B of Summit Therapeutics stock for Q1 2025, up 15% quarter-over-quarter.
- 42 funds opened new Summit Therapeutics positions in Q1 2025 and 33 closed out, a net change of +9 holders.
- The largest Summit Therapeutics buyer in Q1 2025 was Balyasny Asset Management, an estimated $26.4M added.
- The largest Summit Therapeutics seller in Q1 2025 was Millennium Management, an estimated $23.3M sold.
Based on aggregated 13F filings for Q1 2025.